Fibrolamellar Carcinoma, 19p13.1 (PRKACA) Rearrangement, FISH, Tissue
Use
This test is useful for aiding in the diagnosis of fibrolamellar carcinoma through the identification of PRKACA gene rearrangements. The DNAJB1-PRKACA fusion has been associated with a distinct subtype of hepatocellular carcinoma known as fibrolamellar carcinoma. The test employs a FISH probe strategy to detect rearrangement events in the DNAJB1-PRKACA fusion, helping clinicians determine the presence of this specific cancer subtype.
Special Instructions
A pathology report is required for testing, which may include working drafts or preliminary reports. Additionally, a reason for testing must be provided; if not available, Mayo Clinic Laboratories may enter an appropriate indication.
Limitations
This test is not approved by the FDA and serves as an adjunct to existing clinical and pathological information. Non-formalin fixatives may not yield successful FISH assays, but such samples will not be rejected. Paraffin-embedded, decalcified tissues are generally unsuccessful, and the pathologist may need to cancel testing. Slides and H&E used for analysis are retained by the laboratory per CAP and NYS requirements, while extra provided materials are returned post-testing.
New York Approved
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
LOINC Codes
- 104670-5
- 50397-9
- 69965-2
- 62356-1
- 42349-1
- 31208-2
- 80398-1
- 85069-3
- 48767-8
- 62364-5
- 18771-6
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Two consecutive, unstained, 5 micron-thick sections placed on positively charged slides, and 1 hematoxylin and eosin-stained slide.
Container
Formalin-fixed, paraffin-embedded tumor tissue block or slides.
Causes for Rejection
All specimens will be evaluated for test suitability.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Preferred |